# Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

> **NCT04403763** · PHASE1,PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 80 (actual)

## Conditions studied

- Presbyopia

## Interventions

- **DRUG:** AGN-241622
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT04403763
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-27
- **Primary completion:** 2022-12-05
- **Final completion:** 2022-12-05
- **Target enrollment:** 80 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2024-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04403763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04403763, "Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04403763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*